BIOMAT Database Logo BIOMAT Database Logo

Influence of pindolol (Visken) on respiratory function in 20 asthmatic patients. 1978

C C Christensen, and N P Boye, and H Erikson, and G Hansen

The effect of a single oral dose of pindolol on bronchi was studied in a double-blind cross-over trial in 20 adult patients, most of whom had moderate bronchial asthma. A single dose of pindolol 5 mg, sufficient to cause a significant fall in heart rate and blood pressure at rest, did not produce a significant fall in the forced expiratory volume (FEV1.0). However, two patients showed marked deterioration in lung function after pindolol. A conventional therapeutic dose of salbutamol by inhalation produced a significant increase in ventilatory function relative to placebo, but it did not outweigh the bronchial effect of pindolol.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010869 Pindolol A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638) Prindolol,LB-46,Visken,LB 46,LB46
D011674 Pulse The rhythmical expansion and contraction of an ARTERY produced by waves of pressure caused by the ejection of BLOOD from the left ventricle of the HEART as it contracts. Pulses
D012119 Respiration The act of breathing with the LUNGS, consisting of INHALATION, or the taking into the lungs of the ambient air, and of EXHALATION, or the expelling of the modified air which contains more CARBON DIOXIDE than the air taken in (Blakiston's Gould Medical Dictionary, 4th ed.). This does not include tissue respiration ( Breathing
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D005541 Forced Expiratory Volume Measure of the maximum amount of air that can be expelled in a given number of seconds during a FORCED VITAL CAPACITY determination . It is usually given as FEV followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity. Forced Vital Capacity, Timed,Timed Vital Capacity,Vital Capacity, Timed,FEVt,Capacities, Timed Vital,Capacity, Timed Vital,Expiratory Volume, Forced,Expiratory Volumes, Forced,Forced Expiratory Volumes,Timed Vital Capacities,Vital Capacities, Timed,Volume, Forced Expiratory,Volumes, Forced Expiratory

Related Publications

C C Christensen, and N P Boye, and H Erikson, and G Hansen
Influence of metoprolol on hemodynamics and respiratory function in asthmatic patients.
August 1979, International journal of clinical pharmacology and biopharmacy,
C C Christensen, and N P Boye, and H Erikson, and G Hansen
[Effect of treatment with pindolol (Visken) on hemodynamics in patients with primary hypertension].
January 1986, Kardiologia polska,
C C Christensen, and N P Boye, and H Erikson, and G Hansen
Experiments with pindolol (Visken) in healthy volunteers.
September 1977, The Medical journal of Australia,
C C Christensen, and N P Boye, and H Erikson, and G Hansen
[Comparative study on the elimination of pindolol (visken) and antipyrin in patients with liver diseases].
December 1976, Schweizerische medizinische Wochenschrift,
C C Christensen, and N P Boye, and H Erikson, and G Hansen
[Clinical use of pindolol (Visken) in the treatment of arterial hypertension].
February 1977, Srpski arhiv za celokupno lekarstvo,
C C Christensen, and N P Boye, and H Erikson, and G Hansen
Combination therapy of essential hypertension with pindolol (Visken) and hydralazine.
December 1975, European journal of clinical pharmacology,
C C Christensen, and N P Boye, and H Erikson, and G Hansen
Combination therapy of essential hypertension with pindolol (Visken) and hydralazine.
January 1976, Advances in clinical pharmacology,
C C Christensen, and N P Boye, and H Erikson, and G Hansen
Comparative investigation of the respiratory and cardiovascular effect of mepindolol, propranolol and pindolol in asthmatic patients.
June 1978, International journal of clinical pharmacology and biopharmacy,
C C Christensen, and N P Boye, and H Erikson, and G Hansen
Pindolol (Visken) and angina pectoris: a double blind multicentre trial.
September 1972, The New Zealand medical journal,
C C Christensen, and N P Boye, and H Erikson, and G Hansen
[The paradoxical oculocardial reflex and its treatment with pindolol (Visken)].
July 1973, Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. Albrecht von Graefe's archive for clinical and experimental ophthalmology,
Copied contents to your clipboard!